Lantern Pharma

Lantern Pharma completed a Type C meeting with the FDA, receiving critical guidance on the regulatory pathway and trial design for a planned pediatric CNS cancer trial targeting Atypical Teratoid Rhabdoid Tumor (ATRT).

Lantern Pharma achieved complete responses in two separate clinical trials, with LP-300 showing complete tumor response in a 70-year-old never-smoker lung cancer patient and LP-284 demonstrating complete metabolic response in a heavily pretreated lymphoma patient.

Lantern Pharma's LP-284 achieved complete metabolic response in a heavily pretreated diffuse large B-cell lymphoma patient after just two treatment cycles.

Lantern Pharma received European Patent Office allowance for LP-284, a next-generation acylfulvene targeting relapsed or refractory non-Hodgkin's lymphoma with patent exclusivity through early 2039.

A 70-year-old never-smoker with advanced non-small cell lung cancer achieved complete response with LP-300 plus chemotherapy after failing three prior treatment lines including Keytruda, radiation, and Tagrisso.

LP-184 showed remarkable survival improvements in mouse models of atypical teratoid rhabdoid tumors (ATRT), with median survival increasing by 345% in one model (p<0.0001).

• Lantern Pharma's HARMONIC trial for LP-300 demonstrated an impressive 86% clinical benefit rate and 43% objective response rate in never-smoker NSCLC patients, with enrollment expanding in Japan and Taiwan where never-smokers represent up to 40% of NSCLC cases. • LP-184 received FDA Fast Track Designations for both Glioblastoma and Triple Negative Breast Cancer in 2024, plus three additional Rare Pediatric Disease Designations, advancing through Phase 1a trials with early signs of clinical activity at higher dose levels. • The company's proprietary RADR® AI platform surpassed 100 billion oncology-specific data points in 2024, powering precision medicine initiatives and reducing development timelines by 30-50% compared to traditional approaches.

• Lantern Pharma's LP-184 has been granted Fast Track designation by the FDA for treating triple-negative breast cancer, marking its second such designation in 2024. • The drug is currently undergoing a Phase 1A clinical trial to assess its safety and tolerability across various solid tumors, including triple-negative breast cancer. • LP-184 previously received Fast Track designation for glioblastoma in October, highlighting its potential in addressing multiple aggressive cancers. • Lantern Pharma's stock experienced a rise following the announcement, reflecting investor optimism about the drug's development and potential market impact.

The FDA granted Fast Track Designation to Lantern Pharma's LP-184 for treating Triple Negative Breast Cancer (TNBC), marking its second Fast Track Designation in 2024.

Lantern Pharma has dosed the first patient in Taiwan for its Phase 2 HARMONIC trial, evaluating LP-300 in never-smoker NSCLC patients.